Assignee
SHANGHAI AB PHARMATECH LTD
CN·2 granted patents·2 pending applications·0 citations·filing 2022–2024
Top patents by PatentIndex Score
4 records- 0179US2024383858A1Multi-targeted tyrosine kinase inhibitors effective in antitumor usesSHANGHAI AB PHARMATECH LTD·Filed 2024·Application pending·0 cites
- 0278US2024166606A1Multi-targeted tyrosine kinase inhibitors and their pharmaceutical usesSHANGHAI AB PHARMATECH LTD·Filed 2024·Application pending·0 cites
- 0373US12071408B2Multi-targeted tyrosine kinase inhibitors effective in antitumor usesSHANGHAI AB PHARMATECH LTD·Filed 2022·Granted Aug 27, 2024·0 cites·10 claims
- 0473US11912663B2Multi-targeted tyrosine kinase inhibitors and their pharmaceutical usesSHANGHAI AB PHARMATECH LTD·Filed 2022·Granted Feb 27, 2024·0 cites·8 claims
Join the waitlist — get patent alerts
Get an alert when SHANGHAI AB PHARMATECH LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →